How close are we to a Parkinson’s breakthrough? Three experts have their say
Author: Almaz OhenePublished: 23 March 2017
Prep: Cook: Serves:
This year marks 200 years since Dr James Parkinson wrote his essay defining the condition we now know as Parkinson’s disease – but there is still no cure. For this debate piece in our special #UniteForParkinsons series, we speak to Parkinson’s experts around the world to find out how close we could be to a big leap in the search for better treatment and ultimately a cure
A ‘breakthrough’ is defined as a sudden increase in knowledge, improvement in technique, or fundamental advancement in understanding. But what breakthroughs are Parkinson’s researchers and campaigners working towards? And how close are we to achieving those breakthroughs? Here, we ask three world-renowned Parkinson’s experts – Dr Michael Okun, Professor Baastian Bloem and Susanna Lindvall – to share their personal opinions and predictions on each of their fields of expertise.
“Breakthrough ideas and therapies stretch far beyond a single drug”
Dr Michael Okun, Adelaide Lackner professor and chairman of neurology at the Univeristy of Florida
The point that I emphasise with my patients is that breakthrough ideas and therapies in Parkinson’s disease stretch far beyond a single drug or stem cell. There is, in fact, a broader and more exciting picture and portfolio of breakthroughs spanning drug, cell, vaccine, device, genetics, care, and behaviour. Patients and families with personal investments in Parkinson’s disease should be informed and updated about all of the potential breakthrough therapies.
Andy Siderowf and colleagues at the University of Pennsylvania’s National Parkinson Foundation (NPF) Center of Excellence, took another approach to constructing an economic model. The Penn investigators were interested in the ‘economic consequences of slower rates of Parkinson’s progression’. They used a technique called a Markov model and predicted the potential savings associated with slowing Parkinson’s disease progression. Slowing progression by 20% saved the health care system US$60,657 per patient. Stopping disease progression saved US$442,429 per patient.
It is now clear that the weather forecast will be predicting a future storm of Parkinson’s disease cases. This storm will be accompanied by a downpour of large hospital bills and an insurmountable economic burden. The newly diagnosed Parkinson’s disease cases, when added to the existing patients, will have a social and economic impact on all countries and cultures. It will be important that we advocate for a strategic investment from all nations of the world.
One of the most common questions I receive from Parkinson’s disease patients and families is ‘What will be the next breakthrough therapy?’ Because of the complexity of the disease, each person possesses a different combination of bothersome symptoms. This complexity means that the answer to the next breakthrough therapy will vary patient to patient, and it could be a breakthrough in care as well as possibly a new device or drug. We will need to expand our notion of breakthroughs, and we will need to harness this knowledge to reduce the burden of Parkinson’s disease.
“I see a much greater role for informed, engaged patients”
Professor Bastiaan Bloem, MD, PhD, medical director, Parkinson Center Nijmegen
Breakthroughs in the area of Parkinson’s disease will come from two main directions: the cure and the care. My own research and innovation focus is exclusively on care issues. The major breakthrough that I foresee here is a much greater role for fully informed and engaged patients as equal partners in healthcare, who have easy access to integrated healthcare networks of well-trained professionals who work according to a value-based healthcare concept.
Care will be delivered largely outside institutions and within the patient’s own home environment, and increasingly via telemedicine approaches. This and other technological developments will help to drive these aforementioned innovations. Implementing this into the western world will take at least 10 more years, and unfortunately, much longer in less developed countries.
“In the next 10 years I hope we will have effective methods for early diagnosis”
Susanna Lindvall, vice-president of Parkinson’s Europe
Until now, Parkinson’s treatments have focused on symptom management in terms of drug-based treatments and surgical treatments such as deep brain stimulation. Now, there are several drugs in the pipeline – such as MSDC-0160, a drug originally created to treat Type-2 diabetes and the Transeuro trial of cell therapy (transplantation).
In the coming 10 years I hope we will have effective methods for early diagnosis. Right now, researchers have developed a new test that is able to detect abnormal alpha-synuclein in the spinal fluid of people with Parkinson’s with remarkable specificity and sensitivity, at an early stage of the disease. It is early days, but the test is promising. There is also a new neuro-protective strategy where LRRK2 kinase inhibitors are being trialled as therapies for Parkinson’s disease. Researchers have discovered an interaction in neurons that contributes to Parkinson’s disease, and they have shown that drugs currently in development may block the process. The hope is that these will bring major improvements in the quality of life for people with Parkinson’s – life expectancy will improve and the progression of the condition may be slowed or even stopped.
Michael Okun, MD
Michael is an internationally renowned neurologist and leading researcher. He is currently the Adelaide Lackner professor and chairman of neurology at the University of Florida and is the medical director at the US-based organisation, Parkinson’s Foundation. He was honoured at the White House in 2015 as a Champion of Change for Parkinson’s disease.
Professor Baastian Bloem
Bas Bloem is a consultant neurologist at the Department of Neurology, Radboud University Nijmegen Medical Centre, the Netherlands. In 1994, he obtained his PhD degree at the Leiden University Medical Centre, the Netherlands. In 2002, he founded and became medical director of Parkinson Centre Nijmegen (ParC), which was recognised from 2005 onwards as centre of excellence for Parkinson’s disease. Together with Dr Marten Munneke, he also developed ParkinsonNet, where people with Parkinson’s “co-design” their treatment programme in collaboration with a dedicated, multi-disciplinary team– accessed via ParkinsonNet’s online database of expert practitioners.
Susanna has been the vice-president of the Parkinson’s Europe since 2005. She was born in Romania but has lived in Sweden since 1962, where she graduated as a BSc in organic chemistry at the University of Stockholm. From 1996 to 2002 she was President of the Swedish Parkinson’s Disease Association (SPA). She worked for many years as an information specialist at dairy company Arla Foods until her retirement in 2010.
Parkinson’s UK and the Parkinson’s Europe are running the #UniteForParkinsons campaign to coincide with World Parkinson’s Day on 11 April. Get involved by using the hashtag on social media and visit the website here
World Parkinson Congress 2019 Bloggers: Sharon Krischer
#WPC2019: We talk to American blogger Sharon Krischer
8 months ago
35 new Parkinson’s drug trials launched in last year
Researchers launched 35 new clinical trials of Parkinson’s drug therapies in the last year, according to recent findings published in the ‘Journal of Parkinson’s Disease’. The 2023 Parkinson’s drug development pipeline report noted a slight decrease in active trials compared to the 2022 update (down from 147 to 139 overall). About one-third of trials were still in Phase 1, half were in Phase 2 – and just 20 (14%) were in Phase 3, raising concerns about ‘slow progress’. However, of the active trials logged on ClinicalTrials.gov at the time of the latest report, 35 were found to be newly registered. The report authors concluded: “The slow progress and lack of agents transitioning from Phase 2 to Phase 3 is concerning, but collective efforts by various stakeholders are being made to accelerate the clinical trial process, with the aim of bringing new therapies to the [Parkinson’s] community sooner.”
Parkinson’s Europe co-founder Lizzie Graham wins World Parkinson Coalition award
Parkinson’s Europe co-founder Lizzie Graham has won a World Parkinson Coalition (WPC) award for her contribution to the Parkinson’s community. Lizzie is one of four people set to receive the Robin Elliott Award – which is given out every three years to individuals whose efforts best embody the goals and ethos of the WPC. She will be presented with the award in a ceremony at the World Parkinson’s Congress, which will be held in Barcelona later this year. Commenting on the news of Lizzie’s award, Parkinson’s Europe President, Veronica Clark, said: “Lizzie is Lizzie, and we love her for who she is and what she has done for us all – for people with Parkinson’s past and present and, I’m sure, future.” Lizzie co-founded the European Parkinson’s Disease Association (renamed Parkinson’s Europe last year) in 1992. She has since held several roles within the organisation – including secretary general and…
Study explores predictors of cognitive impairment in Parkinson’s disease
Cognitive impairment can affect some people with Parkinson’s – and may greatly impact their quality of life. Now, researchers in China have examined the possible risk factors for cognitive impairment in those with the condition. The study analysed data from 409 people with Parkinson’s within two years of their involvement in the Parkinson’s Progression Markers Initiative (PPMI) – an international study that follows people with and without the condition over time. The participants, who were newly diagnosed and experiencing normal cognitive function at the start of the research, were studied for at least five years. Published in ‘Frontiers in Aging Neuroscience’, the results indicate that older age at onset, high blood pressure and worse baseline motor symptoms may be among factors that could contribute to an increased risk of developing cognitive impairment. The researchers cautioned that “a larger sample and much more comprehensive assessment, and prolonged follow-up, will be required”.